Literature DB >> 16211230

Pharmacological breast cancer therapy (review).

Patrick M Navolanic1, James A McCubrey.   

Abstract

Breast cancer ranks as the second most common cause of cancer death among women in the United States. Anticancer agents are an important component of breast cancer therapy. Drugs frequently used to treat breast cancer include methotrexate, 5-fluorouracil (5-FU), cyclophosphamide, anthracyclines, taxanes, trastuzumab, tamoxifen, and aromatase inhibitors. These agents inhibit breast cancer progression by a variety of different mechanisms. This review describes each of these drugs and the varying effects each of them have upon breast cancer cells.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16211230

Source DB:  PubMed          Journal:  Int J Oncol        ISSN： 1019-6439            Impact factor:   5.650


  7 in total

1.  Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.

Authors:  Melissa Sokolosky; William H Chappell; Kristin Stadelman; Stephen L Abrams; Nicole M Davis; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

2.  Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats.

Authors:  Yi-Sheng He; Wei Sun; Chong-Zhi Wang; Lian-Wen Qi; Jie Yang; Ping Li; Xiao-Dong Wen; Chun-Su Yuan
Journal:  Biomed Chromatogr       Date:  2014-10-22       Impact factor: 1.902

3.  Reactions of Trimethylsilyl Fluorosulfonyldifluoroacetate with Purine and Pyrimidine Nucleosides.

Authors:  Magdalena Rapp; Xiaohong Cai; Wei Xu; William R Dolbier; Stanislaw F Wnuk
Journal:  J Fluor Chem       Date:  2009-03-01       Impact factor: 2.050

4.  Influence of 5-fluorouracil on ferredoxin reductase mRNA splice variants in colorectal carcinomas.

Authors:  Mark Schneider; Motoko Tanaka-Nozaki; Shunji Kato; Brunhilde Blömeke
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

Review 5.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

6.  Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.

Authors:  Melissa L Sokolosky; Kristin M Stadelman; William H Chappell; Stephen L Abrams; Alberto M Martelli; Franca Stivala; Massimo Libra; Ferdinando Nicoletti; Lyudmyla B Drobot; Richard A Franklin; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2011-07

7.  Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.

Authors:  Meng-Lay Lin; Jae-Hyun Park; Toshihiko Nishidate; Yusuke Nakamura; Toyomasa Katagiri
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.